For questions about financial assistance,
call 1-844-DUPIXENT, option 1 or
click to learn more
Patient portrayal
DUPIXENT was studied in two 24-week clinical trials in 284 patients ages 12 years and older with chronic
spontaneous urticaria (CSU) who continued to have hives despite taking H1 antihistamines. All patients
remained on antihistamines during the trials.
DUPIXENT's use for treating CSU in children ages 2-11 years is supported by the results
from two studies that included patients 12 years of age and older with CSU.
*Patients rated their itch daily (on a scale from 0 to 3) for 7 days (maximum score of 21), and this number
was compared to their baseline score.
†Patients rated their hives daily (on a scale from 0 to 3) for 7 days (maximum score of 21). This score was added
to their itch severity score and compared to the baseline score.
View the possible side effects of DUPIXENT.
The safety of DUPIXENT was assessed in 18 patients 2-11 years of age
who received DUPIXENT based on weight. No new side effects were
identified in pediatric patients 2-11 years old who received DUPIXENT.